Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.48 |
| ▸ | ITGAV | P06756 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8968592 | 1.00 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL12087999 | 0.97 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL12088102 | 0.95 | SIRT2 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL15827333 | 0.89 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL2010522 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL15827332 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL2007693 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL8387978 | 0.84 | FOLH1 (0.65) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL10421088 | 0.84 | FOLH1 (0.62) | FOLH1SIRT2SIRT1IDO1TDO2 | |
| SCHEMBL2640680 | 0.81 | ALDH1A1 (0.51) | IDO1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1622618-A4 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7354923-B2 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1425029-A4 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005102340-A1 | PIPERAZINE MELANOCORTIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224957-A1 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-11 | — | — | US | disclosed |
| US-20040171520-A1 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1425029-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | Palatin Technologies, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003013571-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | MC1R, MC5R, MC3R | CYP3A4 4536/4885CYP2D6 3878/4885CYP2C9 4580/4885 |
| US-20040171520-A1 | Peptidomimetics of biologically active metallopeptides | MC1R, MC4R, MC5R | CYP3A4 3806/4885CYP2D6 2484/4885CYP2C9 4322/4885 |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | MC1R, MC3R, MC5R | CYP3A4 2965/4885CYP2D6 2193/4885CYP2C9 2450/4885 |
| US-20040224957-A1 | Melanocortin receptor-specific compounds | MC1R, MC5R, MC3R | CYP3A4 2117/4885CYP2D6 1727/4885CYP2C9 2411/4885 |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | CYP3A4 2689/4885CYP2D6 1768/4885CYP2C9 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.